Currently, CSF p-tau181, Aβ42/40, and total tau are used to diagnose AD in clinical practice.1 P-tau217 has recently gained attention due to its high sensitivity and specificity for AD, which are both slightly higher than p-tau181. In plasma, generally speaking, the diagnostic performance of most biomarkers is lower due to difficulties in measuring very low concentrations of abnormal proteins that are present in the blood. The exception is plasma p-tau217, which has excellent diagnostic performance in plasma.2,3 In fact, plasma p-tau217 has statistically non-distinguishable performance from currently used CSF biomarkers. Therefore, plasma p-tau217 will likely have an important role in the future clinical diagnosis of Alzheimer’s disease.2,3
Related content
Stroke, migraine, Alzheimer’s Disease and other dementias were among the top ten conditions that accounted for the greatest nervous system DALYs in 2021
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease and the leading cause of dementia worldwide, regardless of socioeconomic status.
Dementia is an umbrella term used to describe a state where an individual has lost the ability to carry out daily life activities independently because of cognitive impairment that is not due to an underlying psychiatric condition. Alzheimer’s disease (AD) refers to the abnormal presence of Aβ and tau proteins, which define AD among many other neurodegenerative diseases. Dementia -including dementia due to AD- is likely to be underestimated because of underdiagnosis and misdiagnosis.